ENGLEWOOD CLIFFS, N.J., Jan. 10 /PRNewswire-FirstCall/ -- EpiCept Corporation announced today that it will start trading on the Nordic Exchange in Stockholm beginning on January 11, 2006. The company has received a secondary listing on the Stock Exchange’s O List and will be traded under the symbol “EPCT”.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
EpiCept completed its merger with Maxim Pharmaceuticals Inc. on January 4, 2006. Maxim had been listed on the Stockholm Stock Exchange since October 24, 1997. EpiCept began trading on the Nasdaq National Market system under the symbol “EPCT” on January 5, 2006.
About EpiCept Corporation
EpiCept is an emerging pharmaceutical company focused on unmet needs in the treatment of pain and cancer. The company has a staged portfolio with several pain therapies in late-stage clinical trials, and a lead oncology compound (for AML) with demonstrated efficacy in a Phase III trial; the compound is intended for commercialization in Europe. EpiCept is based in New Jersey, and the company’s R&D team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.
Photo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGOEpiCept Corporation
CONTACT: Robert Cook of EpiCept Corporation, +1-201-894-8980,rcook@epicept.com; or, Lev Janashvili of Feinstein Kean Healthcare,+1-617-761-6731, lev.janashvili@fkhealth.com, for EpiCept Corporation
Web site: http://www.epicept.com/
